



US010279247B2

(12) **United States Patent**  
**Kiani**

(10) **Patent No.:** **US 10,279,247 B2**  
(45) **Date of Patent:** **May 7, 2019**

(54) **AVATAR-INCENTIVE HEALTHCARE THERAPY**

(58) **Field of Classification Search**

USPC ..... 434/257  
See application file for complete search history.

(71) Applicant: **MASIMO CORPORATION**, Irvine, CA (US)

(56) **References Cited**

(72) Inventor: **Massi Joe E. Kiani**, Laguna Niguel, CA (US)

U.S. PATENT DOCUMENTS

(73) Assignee: **Masimo Corporation**, Irvine, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 562 days.

4,960,128 A	10/1990	Gordon et al.
4,964,408 A	10/1990	Hink et al.
5,041,187 A	8/1991	Hink et al.
5,069,213 A	12/1991	Polczynski
5,163,438 A	11/1992	Gordon et al.
5,319,355 A	6/1994	Russek
5,337,744 A	8/1994	Branigan
5,341,805 A	8/1994	Stavridi et al.
D353,195 S	12/1994	Savage et al.
D353,196 S	12/1994	Savage et al.
5,377,676 A	1/1995	Vari et al.
D359,546 S	6/1995	Savage et al.
5,431,170 A	7/1995	Mathews
D361,840 S	8/1995	Savage et al.
D362,063 S	9/1995	Savage et al.
5,452,717 A	9/1995	Branigan et al.
D363,120 S	10/1995	Savage et al.

(Continued)

(21) Appl. No.: **14/571,286**

(22) Filed: **Dec. 15, 2014**

(65) **Prior Publication Data**

US 2015/0165312 A1 Jun. 18, 2015

**Related U.S. Application Data**

(60) Provisional application No. 61/916,136, filed on Dec. 13, 2013.

*Primary Examiner* — Kesha Frisby

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(51) **Int. Cl.**

<b>A63F 13/212</b>	(2014.01)
<b>A61B 5/00</b>	(2006.01)
<b>A61B 5/0205</b>	(2006.01)
<b>A61B 5/024</b>	(2006.01)
<b>A61B 5/021</b>	(2006.01)
<b>A61B 5/145</b>	(2006.01)
<b>A61B 5/1455</b>	(2006.01)


(57) **ABSTRACT**

An avatar-incentive healthcare therapy system has a physiological monitor for generating a physiological parameter indicative of physical health. An academic test for generating a test score is indicative of mental acuity. The avatar has outward characteristics and game play capabilities proportional to the physiological health and the mental acuity so as to incentivize improved physical health and academic performance.

(52) **U.S. Cl.**

CPC ..... **A63F 13/212** (2014.09); **A61B 5/0205** (2013.01); **A61B 5/744** (2013.01); **A61B 5/0022** (2013.01); **A61B 5/021** (2013.01); **A61B 5/024** (2013.01); **A61B 5/1455** (2013.01); **A61B 5/14532** (2013.01)

**7 Claims, 5 Drawing Sheets**



(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,456,252	A	10/1995	Vari et al.	6,368,283	B1	4/2002	Xu et al.
5,479,934	A	1/1996	Imran	6,371,921	B1	4/2002	Caro et al.
5,482,036	A	1/1996	Diab et al.	6,377,829	B1	4/2002	Al-Ali
5,490,505	A	2/1996	Diab et al.	6,388,240	B2	5/2002	Schulz et al.
5,494,043	A	2/1996	O'Sullivan et al.	6,397,091	B2	5/2002	Diab et al.
5,533,511	A	7/1996	Kaspari et al.	6,430,437	B1	8/2002	Marro
5,534,851	A	7/1996	Russek	6,430,525	B1	8/2002	Weber et al.
5,561,275	A	10/1996	Savage et al.	6,463,311	B1	10/2002	Diab
5,562,002	A	10/1996	Lalin	6,470,199	B1	10/2002	Kopotic et al.
5,590,649	A	1/1997	Caro et al.	6,501,975	B2	12/2002	Diab et al.
5,602,924	A	2/1997	Durand et al.	6,505,059	B1	1/2003	Kollias et al.
5,632,272	A	5/1997	Diab et al.	6,515,273	B2	2/2003	Al-Ali
5,638,816	A	6/1997	Kiani-Azarbayjany et al.	6,519,487	B1	2/2003	Parker
5,638,818	A	6/1997	Diab et al.	6,525,386	B1	2/2003	Mills et al.
5,645,440	A	7/1997	Tobler et al.	6,526,300	B1	2/2003	Kiani et al.
5,685,299	A	11/1997	Diab et al.	6,541,756	B2	4/2003	Schulz et al.
D393,830	S	4/1998	Tobler et al.	6,542,764	B1	4/2003	Al-Ali et al.
5,743,262	A	4/1998	Lepper, Jr. et al.	6,580,086	B1	6/2003	Schulz et al.
5,758,644	A	6/1998	Diab et al.	6,584,336	B1	6/2003	Ali et al.
5,760,910	A	6/1998	Lepper, Jr. et al.	6,595,316	B2	7/2003	Cybulski et al.
5,769,785	A	6/1998	Diab et al.	6,597,932	B2	7/2003	Tian et al.
5,782,757	A	7/1998	Diab et al.	6,597,933	B2	7/2003	Kiani et al.
5,785,659	A	7/1998	Caro et al.	6,606,511	B1	8/2003	Ali et al.
5,791,347	A	8/1998	Flaherty et al.	6,632,181	B2	10/2003	Flaherty et al.
5,810,734	A	9/1998	Caro et al.	6,639,668	B1	10/2003	Trepagnier
5,823,950	A	10/1998	Diab et al.	6,640,116	B2	10/2003	Diab
5,830,131	A	11/1998	Caro et al.	6,643,530	B2	11/2003	Diab et al.
5,833,618	A	11/1998	Caro et al.	6,650,917	B2	11/2003	Diab et al.
5,860,919	A	1/1999	Kiani-Azarbayjany et al.	6,654,624	B2	11/2003	Diab et al.
5,890,929	A	4/1999	Mills et al.	6,658,276	B2	12/2003	Kiani et al.
5,904,654	A	5/1999	Wohltmann et al.	6,661,161	B1	12/2003	Lanzo et al.
5,919,134	A	7/1999	Diab	6,671,531	B2	12/2003	Al-Ali et al.
5,934,925	A	8/1999	Tobler et al.	6,678,543	B2	1/2004	Diab et al.
5,940,182	A	8/1999	Lepper, Jr. et al.	6,684,090	B2	1/2004	Ali et al.
5,987,343	A	11/1999	Kinast	6,684,091	B2	1/2004	Parker
5,995,855	A	11/1999	Kiani et al.	6,697,656	B1	2/2004	Al-Ali
5,997,343	A	12/1999	Mills et al.	6,697,657	B1	2/2004	Shehada et al.
6,002,952	A	12/1999	Diab et al.	6,697,658	B2	2/2004	Al-Ali
6,011,986	A	1/2000	Diab et al.	RE38,476	E	3/2004	Diab et al.
6,027,452	A	2/2000	Flaherty et al.	6,699,194	B1	3/2004	Diab et al.
6,036,642	A	3/2000	Diab et al.	6,714,804	B2	3/2004	Al-Ali et al.
6,045,509	A	4/2000	Caro et al.	RE38,492	E	4/2004	Diab et al.
6,067,462	A	5/2000	Diab et al.	6,721,582	B2	4/2004	Trepagnier et al.
6,081,735	A	6/2000	Diab et al.	6,721,585	B1	4/2004	Parker
6,088,607	A	7/2000	Diab et al.	6,725,075	B2	4/2004	Al-Ali
6,110,522	A	8/2000	Lepper, Jr. et al.	6,728,560	B2	4/2004	Kollias et al.
6,124,597	A	9/2000	Shehada	6,735,459	B2	5/2004	Parker
6,128,521	A	10/2000	Marro et al.	6,745,060	B2	6/2004	Diab et al.
6,129,675	A	10/2000	Jay	6,760,607	B2	7/2004	Al-Ali
6,144,868	A	11/2000	Parker	6,770,028	B1	8/2004	Ali et al.
6,151,516	A	11/2000	Kiani-Azarbayjany et al.	6,771,994	B2	8/2004	Kiani et al.
6,152,754	A	11/2000	Gerhardt et al.	6,792,300	B1	9/2004	Diab et al.
6,157,850	A	12/2000	Diab et al.	6,813,511	B2	11/2004	Diab et al.
6,165,005	A	12/2000	Mills et al.	6,816,741	B2	11/2004	Diab
6,184,521	B1	2/2001	Coffin, IV et al.	6,822,564	B2	11/2004	Al-Ali
6,206,830	B1	3/2001	Diab et al.	6,826,419	B2	11/2004	Diab et al.
6,229,856	B1	5/2001	Diab et al.	6,830,711	B2	12/2004	Mills et al.
6,232,609	B1	5/2001	Snyder et al.	6,850,787	B2	2/2005	Weber et al.
6,236,872	B1	5/2001	Diab et al.	6,850,788	B2	2/2005	Al-Ali
6,241,683	B1	6/2001	Macklem et al.	6,852,083	B2	2/2005	Caro et al.
6,253,097	B1	6/2001	Aronow et al.	6,861,639	B2	3/2005	Al-Ali
6,256,523	B1	7/2001	Diab et al.	6,898,452	B2	5/2005	Al-Ali et al.
6,263,222	B1	7/2001	Diab et al.	6,920,345	B2	7/2005	Al-Ali et al.
6,278,522	B1	8/2001	Lepper, Jr. et al.	6,931,268	B1	8/2005	Kiani-Azarbayjany et al.
6,280,213	B1	8/2001	Tobler et al.	6,934,570	B2	8/2005	Kiani et al.
6,285,896	B1	9/2001	Tobler et al.	6,939,305	B2	9/2005	Flaherty et al.
6,301,493	B1	10/2001	Marro et al.	6,943,348	B1	9/2005	Coffin, IV
6,308,089	B1	10/2001	von der Ruhr et al.	6,950,687	B2	9/2005	Al-Ali
6,317,627	B1	11/2001	Ennen et al.	6,961,598	B2	11/2005	Diab
6,321,100	B1	11/2001	Parker	6,970,792	B1	11/2005	Diab
6,325,761	B1	12/2001	Jay	6,979,812	B2	12/2005	Al-Ali
6,334,065	B1	12/2001	Al-Ali et al.	6,985,764	B2	1/2006	Mason et al.
6,343,224	B1	1/2002	Parker	6,993,371	B2	1/2006	Kiani et al.
6,349,228	B1	2/2002	Kiani et al.	6,996,427	B2	2/2006	Ali et al.
6,360,114	B1	3/2002	Diab et al.	6,999,904	B2	2/2006	Weber et al.
				7,003,338	B2	2/2006	Weber et al.
				7,003,339	B2	2/2006	Diab et al.
				7,015,451	B2	3/2006	Dalke et al.
				7,024,233	B2	4/2006	Ali et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,027,849	B2	4/2006	Al-Ali	7,618,375	B2	11/2009	Flaherty
7,030,749	B2	4/2006	Al-Ali	D606,659	S	12/2009	Kiani et al.
7,039,449	B2	5/2006	Al-Ali	7,647,083	B2	1/2010	Al-Ali et al.
7,041,060	B2	5/2006	Flaherty et al.	D609,193	S	2/2010	Al-Ali et al.
7,044,918	B2	5/2006	Diab	D614,305	S	4/2010	Al-Ali et al.
7,048,687	B1	5/2006	Reuss et al.	RE41,317	E	5/2010	Parker
7,067,893	B2	6/2006	Mills et al.	7,729,733	B2	6/2010	Al-Ali et al.
7,096,052	B2	8/2006	Mason et al.	7,734,320	B2	6/2010	Al-Ali
7,096,054	B2	8/2006	Abdul-Hafiz et al.	7,761,127	B2	7/2010	Al-Ali et al.
7,132,641	B2	11/2006	Schulz et al.	7,761,128	B2	7/2010	Al-Ali et al.
7,142,901	B2	11/2006	Kiani et al.	7,764,982	B2	7/2010	Dalke et al.
7,149,561	B2	12/2006	Diab	D621,516	S	8/2010	Kiani et al.
7,186,966	B2	3/2007	Al-Ali	7,791,155	B2	9/2010	Diab
7,190,261	B2	3/2007	Al-Ali	7,801,581	B2	9/2010	Diab
7,215,984	B2	5/2007	Diab	7,822,452	B2	10/2010	Schurman et al.
7,215,986	B2	5/2007	Diab	RE41,912	E	11/2010	Parker
7,221,971	B2	5/2007	Diab	7,844,313	B2	11/2010	Kiani et al.
7,225,006	B2	5/2007	Al-Ali et al.	7,844,314	B2	11/2010	Al-Ali
7,225,007	B2	5/2007	Al-Ali	7,844,315	B2	11/2010	Al-Ali
RE39,672	E	6/2007	Shehada et al.	7,865,222	B2	1/2011	Weber et al.
7,239,905	B2	7/2007	Kiani-Azarbayjany et al.	7,873,497	B2	1/2011	Weber et al.
7,245,953	B1	7/2007	Parker	7,880,606	B2	2/2011	Al-Ali
7,254,429	B2	8/2007	Schurman et al.	7,880,626	B2	2/2011	Al-Ali et al.
7,254,431	B2	8/2007	Al-Ali	7,891,355	B2	2/2011	Al-Ali et al.
7,254,433	B2	8/2007	Diab et al.	7,894,868	B2	2/2011	Al-Ali et al.
7,254,434	B2	8/2007	Schulz et al.	7,899,507	B2	3/2011	Al-Ali et al.
7,272,425	B2	9/2007	Al-Ali	7,899,518	B2	3/2011	Trepagnier et al.
7,274,955	B2	9/2007	Kiani et al.	7,904,132	B2	3/2011	Weber et al.
D554,263	S	10/2007	Al-Ali	7,909,772	B2	3/2011	Popov et al.
7,280,858	B2	10/2007	Al-Ali et al.	7,910,875	B2	3/2011	Al-Ali
7,289,835	B2	10/2007	Mansfield et al.	7,919,713	B2	4/2011	Al-Ali et al.
7,292,883	B2	11/2007	De Felice et al.	7,937,128	B2	5/2011	Al-Ali
7,295,866	B2	11/2007	Al-Ali	7,937,129	B2	5/2011	Mason et al.
7,328,053	B1	2/2008	Diab et al.	7,937,130	B2	5/2011	Diab et al.
7,332,784	B2	2/2008	Mills et al.	7,941,199	B2	5/2011	Kiani
7,340,287	B2	3/2008	Mason et al.	7,951,086	B2	5/2011	Flaherty et al.
7,341,559	B2	3/2008	Schulz et al.	7,957,780	B2	6/2011	Lamego et al.
7,343,186	B2	3/2008	Lamego et al.	7,962,188	B2	6/2011	Kiani et al.
D566,282	S	4/2008	Al-Ali et al.	7,962,190	B1	6/2011	Diab et al.
7,355,512	B1	4/2008	Al-Ali	7,976,472	B2	7/2011	Kiani
7,356,365	B2	4/2008	Schurman	7,988,637	B2	8/2011	Diab
7,371,981	B2	5/2008	Abdul-Hafiz	7,990,382	B2	8/2011	Kiani
7,373,193	B2	5/2008	Al-Ali et al.	7,991,446	B2	8/2011	Al-Ali et al.
7,373,194	B2	5/2008	Weber et al.	8,000,761	B2	8/2011	Al-Ali
7,376,453	B1	5/2008	Diab et al.	8,008,088	B2	8/2011	Bellott et al.
7,377,794	B2	5/2008	Al Ali et al.	RE42,753	E	9/2011	Kiani-Azarbayjany et al.
7,377,899	B2	5/2008	Weber et al.	8,019,400	B2	9/2011	Diab et al.
7,383,070	B2	6/2008	Diab et al.	8,028,701	B2	10/2011	Al-Ali et al.
7,415,297	B2	8/2008	Al-Ali et al.	8,029,765	B2	10/2011	Bellott et al.
7,428,432	B2	9/2008	Ali et al.	8,036,727	B2	10/2011	Schurman et al.
7,438,683	B2	10/2008	Al-Ali et al.	8,036,728	B2	10/2011	Diab et al.
7,440,787	B2	10/2008	Diab	8,046,040	B2	10/2011	Ali et al.
7,454,240	B2	11/2008	Diab et al.	8,046,041	B2	10/2011	Diab et al.
7,467,002	B2	12/2008	Weber et al.	8,046,042	B2	10/2011	Diab et al.
7,469,157	B2	12/2008	Diab et al.	8,048,040	B2	11/2011	Kiani
7,471,969	B2	12/2008	Diab et al.	8,050,728	B2	11/2011	Al-Ali et al.
7,471,971	B2	12/2008	Diab et al.	RE43,169	E	2/2012	Parker
7,483,729	B2	1/2009	Al-Ali et al.	8,118,620	B2	2/2012	Al-Ali et al.
7,483,730	B2	1/2009	Diab et al.	8,126,528	B2	2/2012	Diab et al.
7,489,958	B2	2/2009	Diab et al.	8,128,572	B2	3/2012	Diab et al.
7,496,391	B2	2/2009	Diab et al.	8,130,105	B2	3/2012	Al-Ali et al.
7,496,393	B2	2/2009	Diab et al.	8,145,287	B2	3/2012	Diab et al.
D587,657	S	3/2009	Al-Ali et al.	8,150,487	B2	4/2012	Diab et al.
7,499,741	B2	3/2009	Diab et al.	8,175,672	B2	5/2012	Parker
7,499,835	B2	3/2009	Weber et al.	8,180,420	B2	5/2012	Diab et al.
7,500,950	B2	3/2009	Al-Ali et al.	8,182,443	B1	5/2012	Kiani
7,509,154	B2	3/2009	Diab et al.	8,185,180	B2	5/2012	Diab et al.
7,509,494	B2	3/2009	Al-Ali	8,190,223	B2	5/2012	Al-Ali et al.
7,510,849	B2	3/2009	Schurman et al.	8,190,227	B2	5/2012	Diab et al.
7,526,328	B2	4/2009	Diab et al.	8,203,438	B2	6/2012	Kiani et al.
7,530,942	B1	5/2009	Diab	8,203,704	B2	6/2012	Merritt et al.
7,530,949	B2	5/2009	Al Ali et al.	8,204,566	B2	6/2012	Schurman et al.
7,530,955	B2	5/2009	Diab et al.	8,219,172	B2	7/2012	Schurman et al.
7,563,110	B2	7/2009	Al-Ali et al.	8,224,411	B2	7/2012	Al-Ali et al.
7,596,398	B2	9/2009	Al-Ali et al.	8,228,181	B2	7/2012	Al-Ali
				8,229,533	B2	7/2012	Diab et al.
				8,233,955	B2	7/2012	Al-Ali et al.
				8,244,325	B2	8/2012	Al-Ali et al.
				8,255,026	B1	8/2012	Al-Ali

(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,255,027 B2	8/2012	Al-Ali et al.	8,670,814 B2	3/2014	Diab et al.
8,255,028 B2	8/2012	Al-Ali et al.	8,676,286 B2	3/2014	Weber et al.
8,260,577 B2	9/2012	Weber et al.	8,682,407 B2	3/2014	Al-Ali
8,265,723 B1	9/2012	McHale et al.	RE44,823 E	4/2014	Parker
8,274,360 B2	9/2012	Sampath et al.	RE44,875 E	4/2014	Kiani et al.
8,280,473 B2	10/2012	Al-Ali	8,690,799 B2	4/2014	Telfort et al.
8,301,217 B2	10/2012	Al-Ali et al.	8,700,112 B2	4/2014	Kiani
8,306,596 B2	11/2012	Schurman et al.	8,702,627 B2	4/2014	Telfort et al.
8,310,336 B2	11/2012	Muhsin et al.	8,706,179 B2	4/2014	Parker
8,315,683 B2	11/2012	Al-Ali et al.	8,712,494 B1	4/2014	MacNeish, III et al.
RE43,860 E	12/2012	Parker	8,715,206 B2	5/2014	Telfort et al.
8,337,403 B2	12/2012	Al-Ali et al.	8,718,735 B2	5/2014	Lamego et al.
8,346,330 B2	1/2013	Lamego	8,718,737 B2	5/2014	Diab et al.
8,353,842 B2	1/2013	Al-Ali et al.	8,718,738 B2	5/2014	Blank et al.
8,355,766 B2	1/2013	MacNeish, III et al.	8,720,249 B2	5/2014	Al-Ali
8,359,080 B2	1/2013	Diab et al.	8,721,541 B2	5/2014	Al-Ali et al.
8,364,223 B2	1/2013	Al-Ali et al.	8,721,542 B2	5/2014	Al-Ali et al.
8,364,226 B2	1/2013	Diab et al.	8,723,677 B1	5/2014	Kiani
8,374,665 B2	2/2013	Lamego	8,740,792 B1	6/2014	Kiani et al.
8,385,995 B2	2/2013	Al-ali et al.	8,754,776 B2	6/2014	Poeze et al.
8,385,996 B2	2/2013	Smith et al.	8,755,535 B2	6/2014	Telfort et al.
8,388,353 B2	3/2013	Kiani et al.	8,755,856 B2	6/2014	Diab et al.
8,399,822 B2	3/2013	Al-Ali	8,755,872 B1	6/2014	Marinow
8,401,602 B2	3/2013	Kiani	8,761,850 B2	6/2014	Lamego
8,405,608 B2	3/2013	Al-Ali et al.	8,764,671 B2	7/2014	Kiani
8,414,499 B2	4/2013	Al-Ali et al.	8,768,423 B2	7/2014	Shakespeare et al.
8,418,524 B2	4/2013	Al-Ali	8,771,204 B2	7/2014	Telfort et al.
8,423,106 B2	4/2013	Lamego et al.	8,777,634 B2	7/2014	Kiani et al.
8,428,967 B2	4/2013	Olsen et al.	8,781,543 B2	7/2014	Diab et al.
8,430,817 B1	4/2013	Al-Ali et al.	8,781,544 B2	7/2014	Al-Ali et al.
8,437,825 B2	5/2013	Dalvi et al.	8,781,549 B2	7/2014	Al-Ali et al.
8,455,290 B2	6/2013	Siskavich	8,788,003 B2	7/2014	Schurman et al.
8,457,703 B2	6/2013	Al-Ali	8,790,268 B2	7/2014	Al-Ali
8,457,707 B2	6/2013	Kiani	8,801,613 B2	8/2014	Al-Ali et al.
8,463,349 B2	6/2013	Diab et al.	8,821,397 B2	9/2014	Al-Ali et al.
8,466,286 B2	6/2013	Bellot et al.	8,821,415 B2	9/2014	Al-Ali et al.
8,471,713 B2	6/2013	Poeze et al.	8,830,449 B1	9/2014	Lamego et al.
8,473,020 B2	6/2013	Kiani et al.	8,831,700 B2	9/2014	Schurman et al.
8,483,787 B2	7/2013	Al-Ali et al.	8,840,549 B2	9/2014	Al-Ali et al.
8,489,364 B2	7/2013	Weber et al.	8,847,740 B2	9/2014	Kiani et al.
8,498,684 B2	7/2013	Weber et al.	8,849,365 B2	9/2014	Smith et al.
8,504,128 B2	8/2013	Blank et al.	8,852,094 B2	10/2014	Al-Ali et al.
8,509,867 B2	8/2013	Workman et al.	8,852,994 B2	10/2014	Wojtczuk et al.
8,515,509 B2	8/2013	Bruinsma et al.	8,868,147 B2	10/2014	Stippick et al.
8,523,781 B2	9/2013	Al-Ali	8,868,150 B2	10/2014	Al-Ali et al.
8,529,301 B2	9/2013	Al-Ali et al.	8,870,792 B2	10/2014	Al-Ali et al.
8,532,727 B2	9/2013	Ali et al.	8,886,271 B2	11/2014	Kiani et al.
8,532,728 B2	9/2013	Diab et al.	8,888,539 B2	11/2014	Al-Ali et al.
D692,145 S	10/2013	Al-Ali et al.	8,888,708 B2	11/2014	Diab et al.
8,547,209 B2	10/2013	Kiani et al.	8,892,180 B2	11/2014	Weber et al.
8,548,548 B2	10/2013	Al-Ali	8,897,847 B2	11/2014	Al-Ali
8,548,549 B2	10/2013	Schurman et al.	8,909,310 B2	12/2014	Lamego et al.
8,548,550 B2	10/2013	Al-Ali et al.	8,911,377 B2	12/2014	Al-Ali
8,560,032 B2	10/2013	Al-Ali et al.	8,912,909 B2	12/2014	Al-Ali et al.
8,560,034 B1	10/2013	Diab et al.	8,920,317 B2	12/2014	Al-Ali et al.
8,570,167 B2	10/2013	Al-Ali	8,921,699 B2	12/2014	Al-Ali et al.
8,570,503 B2	10/2013	Vo et al.	8,922,382 B2	12/2014	Al-Ali et al.
8,571,617 B2	10/2013	Reichgott et al.	8,929,964 B2	1/2015	Al-Ali et al.
8,571,618 B1	10/2013	Lamego et al.	8,942,777 B2	1/2015	Diab et al.
8,571,619 B2	10/2013	Al-Ali et al.	8,948,834 B2	2/2015	Diab et al.
8,577,431 B2	11/2013	Lamego et al.	8,948,835 B2	2/2015	Diab
8,581,732 B2	11/2013	Al-Ali et al.	8,965,471 B2	2/2015	Lamego
8,584,345 B2	11/2013	Al-Ali et al.	8,983,564 B2	3/2015	Al-Ali
8,588,880 B2	11/2013	Abdul-Hafiz et al.	8,989,831 B2	3/2015	Al-Ali et al.
8,600,467 B2	12/2013	Al-Ali et al.	8,996,085 B2	3/2015	Kiani et al.
8,606,342 B2	12/2013	Diab	8,998,809 B2	4/2015	Kiani
8,626,255 B2	1/2014	Al-Ali et al.	9,022,930 B2 *	5/2015	Sachanandani ..... A61B 5/0205 600/300
8,630,691 B2	1/2014	Lamego et al.	9,028,429 B2	5/2015	Telfort et al.
8,634,889 B2	1/2014	Al-Ali et al.	9,037,207 B2	5/2015	Al-Ali et al.
8,641,631 B2	2/2014	Sierra et al.	9,060,721 B2	6/2015	Reichgott et al.
8,652,060 B2	2/2014	Al-Ali	9,066,666 B2	6/2015	Kiani
8,663,107 B2	3/2014	Kiani	9,066,680 B1	6/2015	Al-Ali et al.
8,666,468 B1	3/2014	Al-Ali	9,072,474 B2	7/2015	Al-Ali et al.
8,667,967 B2	3/2014	Al-Ali et al.	9,078,560 B2	7/2015	Schurman et al.
8,670,811 B2	3/2014	O'Reilly	9,084,569 B2	7/2015	Weber et al.
			9,095,316 B2	8/2015	Welch et al.
			9,106,038 B2	8/2015	Telfort et al.
			9,107,625 B2	8/2015	Telfort et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

9,107,626 B2	8/2015	Al-Ali et al.	D788,312 S	5/2017	Al-Ali et al.
9,113,831 B2	8/2015	Al-Ali	9,636,055 B2	5/2017	Al-Ali et al.
9,113,832 B2	8/2015	Al-Ali	9,636,056 B2	5/2017	Al-Ali
9,119,595 B2	9/2015	Lamego	9,649,054 B2	5/2017	Lamego et al.
9,131,881 B2	9/2015	Diab et al.	9,662,052 B2	5/2017	Al-Ali et al.
9,131,882 B2	9/2015	Al-Ali et al.	9,668,679 B2	6/2017	Schurman et al.
9,131,883 B2	9/2015	Al-Ali	9,668,680 B2	6/2017	Bruinsma et al.
9,131,917 B2	9/2015	Telfort et al.	9,668,703 B2	6/2017	Al-Ali
9,138,180 B1	9/2015	Coverston et al.	9,675,286 B2	6/2017	Diab
9,138,182 B2	9/2015	Al-Ali et al.	9,687,160 B2	6/2017	Kiani
9,138,192 B2	9/2015	Weber et al.	9,693,719 B2	7/2017	Al-Ali et al.
9,142,117 B2	9/2015	Muhsin et al.	9,693,737 B2	7/2017	Al-Ali
9,153,112 B1	10/2015	Kiani et al.	9,697,928 B2	7/2017	Al-Ali et al.
9,153,121 B2	10/2015	Kiani et al.	9,717,425 B2	8/2017	Kiani et al.
9,161,696 B2	10/2015	Al-Ali et al.	9,717,458 B2	8/2017	Lamego et al.
9,161,713 B2	10/2015	Al-Ali et al.	9,724,016 B1	8/2017	Al-Ali et al.
9,167,995 B2	10/2015	Lamego et al.	9,724,024 B2	8/2017	Al-Ali
9,176,141 B2	11/2015	Al-Ali et al.	9,724,025 B1	8/2017	Kiani et al.
9,186,102 B2	11/2015	Bruinsma et al.	9,730,640 B2	8/2017	Diab et al.
9,192,312 B2	11/2015	Al-Ali	9,743,887 B2	8/2017	Al-Ali et al.
9,192,329 B2	11/2015	Al-Ali	9,749,232 B2	8/2017	Sampath et al.
9,192,351 B1	11/2015	Telfort et al.	9,750,442 B2	9/2017	Olsen
9,195,385 B2	11/2015	Al-Ali et al.	9,750,443 B2	9/2017	Smith et al.
9,211,072 B2	12/2015	Kiani	9,750,461 B1	9/2017	Telfort
9,211,095 B1	12/2015	Al-Ali	9,775,545 B2	10/2017	Al-Ali et al.
9,218,454 B2	12/2015	Kiani et al.	9,775,546 B2	10/2017	Diab et al.
9,226,696 B2	1/2016	Kiani	9,775,570 B2	10/2017	Al-Ali
9,241,662 B2	1/2016	Al-Ali et al.	9,778,079 B1	10/2017	Al-Ali et al.
9,245,668 B1	1/2016	Vo et al.	9,782,077 B2	10/2017	Lamego et al.
9,259,185 B2	2/2016	Abdul-Hafiz et al.	9,782,110 B2	10/2017	Kiani
9,267,572 B2	2/2016	Barker et al.	9,787,568 B2	10/2017	Lamego et al.
9,277,880 B2	3/2016	Poeze et al.	9,788,735 B2	10/2017	Al-Ali
9,289,167 B2	3/2016	Diab et al.	9,788,768 B2	10/2017	Al-Ali et al.
9,295,421 B2	3/2016	Kiani et al.	9,795,300 B2	10/2017	Al-Ali
9,307,928 B1	4/2016	Al-Ali et al.	9,795,310 B2	10/2017	Al-Ali
9,323,894 B2	4/2016	Kiani	9,795,358 B2	10/2017	Telfort et al.
D755,392 S	5/2016	Hwang et al.	9,795,739 B2	10/2017	Al-Ali et al.
9,326,712 B1	5/2016	Kiani	9,801,556 B2	10/2017	Kiani
9,333,316 B2	5/2016	Kiani	9,801,588 B2	10/2017	Weber et al.
9,339,220 B2	5/2016	Lamego et al.	9,808,188 B1	11/2017	Perea et al.
9,341,565 B2	5/2016	Lamego et al.	9,814,418 B2	11/2017	Weber et al.
9,351,673 B2	5/2016	Diab et al.	9,820,691 B2	11/2017	Kiani
9,351,675 B2	5/2016	Al-Ali et al.	9,833,152 B2	12/2017	Kiani et al.
9,364,181 B2	6/2016	Kiani et al.	9,833,180 B2	12/2017	Shakespeare et al.
9,368,671 B2	6/2016	Wojtczuk et al.	9,839,379 B2	12/2017	Al-Ali et al.
9,370,325 B2	6/2016	Al-Ali et al.	9,839,381 B1	12/2017	Weber et al.
9,370,326 B2	6/2016	McHale et al.	2006/0161054 A1	7/2006	Reuss et al.
9,370,335 B2	6/2016	Al-Ali et al.	2007/0282478 A1	12/2007	Al-Ali et al.
9,375,185 B2	6/2016	Ali et al.	2009/0247984 A1	10/2009	Lamego et al.
9,386,953 B2	7/2016	Al-Ali	2009/0275813 A1	11/2009	Davis
9,386,961 B2	7/2016	Al-Ali et al.	2009/0275844 A1	11/2009	Al-Ali
9,392,945 B2	7/2016	Al-Ali et al.	2010/0004518 A1	1/2010	Vo et al.
9,397,448 B2	7/2016	Al-Ali et al.	2010/0030040 A1	2/2010	Poeze et al.
9,408,542 B1	8/2016	Kinast et al.	2011/0082711 A1	4/2011	Poeze et al.
9,436,645 B2	9/2016	Al-Ali et al.	2011/0105854 A1	5/2011	Kiani et al.
9,445,759 B1	9/2016	Lamego et al.	2011/0125060 A1	5/2011	Telfort et al.
9,466,919 B2	10/2016	Kiani et al.	2011/0208015 A1	8/2011	Welch et al.
9,474,474 B2	10/2016	Lamego et al.	2011/0230733 A1	9/2011	Al-Ali
9,480,422 B2	11/2016	Al-Ali	2011/0237969 A1	9/2011	Eckerbom et al.
9,480,435 B2	11/2016	Olsen	2012/0165629 A1	6/2012	Merritt et al.
9,492,110 B2	11/2016	Al-Ali et al.	2012/0189990 A1*	7/2012	Bavelier ..... G09B 5/06 434/188
9,510,779 B2	12/2016	Poeze et al.	2012/0209082 A1	8/2012	Al-Ali
9,517,024 B2	12/2016	Kiani et al.	2012/0209084 A1	8/2012	Olsen et al.
9,532,722 B2	1/2017	Lamego et al.	2012/0283524 A1	11/2012	Kiani et al.
9,538,949 B2	1/2017	Al-Ali et al.	2012/0319816 A1	12/2012	Al-Ali
9,538,980 B2	1/2017	Telfort et al.	2013/0023775 A1	1/2013	Lamego et al.
9,549,696 B2	1/2017	Lamego et al.	2013/0041591 A1	2/2013	Lamego
9,554,737 B2	1/2017	Schurman et al.	2013/0060147 A1	3/2013	Welch et al.
9,560,996 B2	2/2017	Kiani	2013/0096405 A1	4/2013	Garfio
9,560,998 B2	2/2017	Al-Ali et al.	2013/0096936 A1	4/2013	Sampath et al.
9,566,019 B2	2/2017	Al-Ali et al.	2013/0243021 A1	9/2013	Siskavich
9,579,039 B2	2/2017	Jansen et al.	2013/0253334 A1	9/2013	Al-Ali et al.
9,591,975 B2	3/2017	Dalvi et al.	2013/0267804 A1	10/2013	Al-Ali
9,622,692 B2	4/2017	Lamego et al.	2013/0296672 A1	11/2013	O'Neil et al.
9,622,693 B2	4/2017	Diab	2013/0296713 A1	11/2013	Al-Ali et al.
			2013/0324808 A1	12/2013	Al-Ali et al.
			2013/0331660 A1	12/2013	Al-Ali et al.
			2014/0012100 A1	1/2014	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2014/0051953 A1 2/2014 Lamego et al.  
 2014/0081100 A1 3/2014 Muhsin et al.  
 2014/0081175 A1 3/2014 Telfort  
 2014/0120564 A1 5/2014 Workman et al.  
 2014/0121482 A1 5/2014 Merritt et al.  
 2014/0127137 A1 5/2014 Bellott et al.  
 2014/0135588 A1 5/2014 Al-Ali et al.  
 2014/0163344 A1 6/2014 Al-Ali  
 2014/0163402 A1 6/2014 Lamego et al.  
 2014/0166076 A1 6/2014 Kiani et al.  
 2014/0171763 A1 6/2014 Diab  
 2014/0180038 A1 6/2014 Kiani  
 2014/0180154 A1 6/2014 Sierra et al.  
 2014/0180160 A1 6/2014 Brown et al.  
 2014/0187973 A1 7/2014 Brown et al.  
 2014/0213864 A1 7/2014 Abdul-Hafiz et al.  
 2014/0266790 A1 9/2014 Al-Ali et al.  
 2014/0275808 A1 9/2014 Poeze et al.  
 2014/0275835 A1\* 9/2014 Lamego ..... A61B 5/0022  
 600/301  
 2014/0275871 A1 9/2014 Lamego et al.  
 2014/0275872 A1 9/2014 Merritt et al.  
 2014/0276115 A1 9/2014 Dalvi et al.  
 2014/0288400 A1 9/2014 Diab et al.  
 2014/0316217 A1 10/2014 Purdon et al.  
 2014/0316218 A1 10/2014 Purdon et al.  
 2014/0316228 A1 10/2014 Blank et al.  
 2014/0323825 A1 10/2014 Al-Ali et al.  
 2014/0323897 A1 10/2014 Brown et al.  
 2014/0323898 A1 10/2014 Purdon et al.  
 2014/0323899 A1\* 10/2014 Silberstein ..... A61B 5/04842  
 600/544  
 2014/0330092 A1 11/2014 Al-Ali et al.  
 2014/0330098 A1 11/2014 Merritt et al.  
 2014/0357966 A1 12/2014 Al-Ali et al.  
 2015/0005600 A1 1/2015 Blank et al.  
 2015/0011907 A1 1/2015 Purdon et al.  
 2015/0012231 A1 1/2015 Poeze et al.  
 2015/0032029 A1 1/2015 Al-Ali et al.  
 2015/0038859 A1 2/2015 Dalvi et al.  
 2015/0045637 A1 2/2015 Dalvi  
 2015/0080754 A1 3/2015 Purdon et al.  
 2015/0087936 A1 3/2015 Al-Ali et al.  
 2015/0094546 A1 4/2015 Al-Ali  
 2015/0097701 A1 4/2015 Al-Ali et al.  
 2015/0099950 A1 4/2015 Al-Ali et al.  
 2015/0099955 A1 4/2015 Al-Ali et al.  
 2015/0101844 A1 4/2015 Al-Ali et al.  
 2015/0106121 A1 4/2015 Muhsin et al.  
 2015/0112151 A1 4/2015 Muhsin et al.  
 2015/0116076 A1 4/2015 Al-Ali et al.  
 2015/0126830 A1 5/2015 Schurman et al.  
 2015/0165312 A1 6/2015 Kiani  
 2015/0196237 A1 7/2015 Lamego  
 2015/0196249 A1 7/2015 Brown et al.  
 2015/0216459 A1 8/2015 Al-Ali et al.  
 2015/0230755 A1 8/2015 Al-Ali et al.  
 2015/0238722 A1 8/2015 Al-Ali  
 2015/0245773 A1 9/2015 Lamego et al.  
 2015/0245794 A1 9/2015 Al-Ali  
 2015/0257689 A1 9/2015 Al-Ali et al.  
 2015/0272514 A1 10/2015 Kiani et al.  
 2015/0351697 A1 12/2015 Weber et al.  
 2015/0351704 A1 12/2015 Kiani et al.

2015/0359429 A1 12/2015 Al-Ali et al.  
 2015/0366507 A1 12/2015 Blank  
 2015/0380875 A1 12/2015 Coverston et al.  
 2016/0029932 A1 2/2016 Al-Ali  
 2016/0051205 A1 2/2016 Al-Ali et al.  
 2016/0058347 A1 3/2016 Reichgott et al.  
 2016/0066823 A1 3/2016 Al-Ali et al.  
 2016/0066824 A1 3/2016 Al-Ali et al.  
 2016/0072429 A1 3/2016 Kiani et al.  
 2016/0081552 A1 3/2016 Wojtczuk et al.  
 2016/0095543 A1 4/2016 Telfort et al.  
 2016/0095548 A1 4/2016 Al-Ali et al.  
 2016/0103598 A1 4/2016 Al-Ali et al.  
 2016/0143548 A1 5/2016 Al-Ali  
 2016/0166182 A1 6/2016 Al-Ali et al.  
 2016/0166183 A1 6/2016 Poeze et al.  
 2016/0192869 A1 7/2016 Kiani et al.  
 2016/0196388 A1 7/2016 Lamego  
 2016/0197436 A1 7/2016 Barker et al.  
 2016/0213281 A1 7/2016 Eckerbom et al.  
 2016/0228043 A1 8/2016 O'Neil et al.  
 2016/0233632 A1 8/2016 Scruggs et al.  
 2016/0234944 A1 8/2016 Schmidt et al.  
 2016/0270735 A1 9/2016 Diab et al.  
 2016/0283665 A1 9/2016 Sampath et al.  
 2016/0287090 A1 10/2016 Al-Ali et al.  
 2016/0287786 A1 10/2016 Kiani  
 2016/0296169 A1 10/2016 McHale et al.  
 2016/0310052 A1 10/2016 Al-Ali et al.  
 2016/0314260 A1 10/2016 Kiani  
 2016/0324486 A1 11/2016 Al-Ali et al.  
 2016/0324488 A1 11/2016 Olsen  
 2016/0327984 A1 11/2016 Al-Ali et al.  
 2016/0328528 A1 11/2016 Al-Ali et al.  
 2016/0331332 A1 11/2016 Al-Ali  
 2016/0367173 A1 12/2016 Dalvi et al.  
 2017/0000394 A1 1/2017 Al-Ali et al.  
 2017/0007134 A1 1/2017 Al-Ali et al.  
 2017/0007190 A1 1/2017 Al-Ali et al.  
 2017/0007198 A1 1/2017 Al-Ali et al.  
 2017/0014083 A1 1/2017 Diab et al.  
 2017/0014084 A1 1/2017 Al-Ali et al.  
 2017/0027456 A1 2/2017 Kinast et al.  
 2017/0042488 A1 2/2017 Muhsin  
 2017/0055851 A1 3/2017 Al-Ali  
 2017/0055882 A1 3/2017 Al-Ali et al.  
 2017/0055887 A1 3/2017 Al-Ali  
 2017/0055896 A1 3/2017 Al-Ali et al.  
 2017/0079594 A1 3/2017 Telfort et al.  
 2017/0086723 A1 3/2017 Al-Ali et al.  
 2017/0143281 A1 5/2017 Olsen  
 2017/0147774 A1 5/2017 Kiani  
 2017/0156620 A1 6/2017 Al-Ali et al.  
 2017/0173632 A1 6/2017 Al-Ali  
 2017/0187146 A1 6/2017 Kiani et al.  
 2017/0188919 A1 7/2017 Al-Ali et al.  
 2017/0196464 A1 7/2017 Jansen et al.  
 2017/0196470 A1 7/2017 Lamego et al.  
 2017/0202490 A1 7/2017 Al-Ali et al.  
 2017/0224231 A1 8/2017 Al-Ali  
 2017/0224262 A1 8/2017 Al-Ali  
 2017/0228516 A1 8/2017 Sampath et al.  
 2017/0245790 A1 8/2017 Al-Ali et al.  
 2017/0251974 A1 9/2017 Shreim et al.  
 2017/0251975 A1 9/2017 Shreim et al.  
 2017/0258403 A1 9/2017 Abdul-Hafiz et al.

\* cited by examiner




FIG. 1B




FIG. 1A




FIG. 2A

FIG. 2B




FIG. 2C




FIG. 3




FIG. 4




FIG. 5

## AVATAR-INCENTIVE HEALTHCARE THERAPY

### PRIORITY CLAIM TO RELATED PROVISIONAL APPLICATIONS

The present application claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 61/916,136 filed Dec. 13, 2013, titled Avatar Incentive Video Game, hereby incorporated in its entirety by reference herein.

### BACKGROUND OF THE INVENTION

Medical device manufacturers are continually increasing the processing capabilities of patient monitors, specifically of patient monitors that process signals based on attenuation of light by patient tissue. In general, such patient monitoring systems include one or more optical sensors that irradiate tissue of a patient and one or more photodetectors that detect the radiation after attenuation thereof by the tissue. The sensor communicates the detected signal to a patient monitor, where the monitor often removes noise and preprocesses the signal. Advanced signal processors then perform time domain and/or frequency domain processing to determine measurements of blood constituents and other physiological parameters of the patient.

Manufacturers have advanced basic pulse oximeters that determine measurements for blood oxygen saturation (“SpO<sub>2</sub>”), pulse rate (“PR”) and pethysmographic information, to read-through-motion oximeters, to co-oximeters that determine measurements of many constituents of circulating blood. For example, Masimo Corporation of Irvine Calif. (“Masimo”) manufactures pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO<sub>2</sub>, PR, perfusion index (“PI”) and others. Masimo sensors include any of LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Masimo oximetry monitors include any of Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.

Many innovations improving the measurement of blood constituents are described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo and are incorporated by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,088,607; 5,782,757 and 5,638,818, assigned to Masimo and hereby incorporated in their entirety by reference herein.

Masimo also manufactures more advanced co-oximeters including Masimo Rainbow® SET, which provides measurements in addition to SpO<sub>2</sub>, such as total hemoglobin (SpHb™), oxygen content (SpCO™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Masimo’s advanced blood parameter monitors include Masimo Radical-7™, Rad87™, and Rad57™ monitors as well as Pronto and Pronto-7 spot check monitors.

Innovations relating to these more advanced blood parameter measurement systems are described in at least U.S. Pat. Nos. 7,647,083; 7,729,733; U.S. Pat. Pub. Nos. 2006/0211925; and 2006/0238358, assigned to Cercacor Laboratories of Irvine, Calif. (“Cercacor”) and hereby incorporated in their entirety by reference herein.

Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including

surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.

Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation (“Masimo”) of Irvine, Calif. and are incorporated in their entirety by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated in their entirety by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO<sub>2</sub>, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.

Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled Multiple Wavelength Sensor Equalization; U.S. Pat. No. 7,729,733, filed Mar. 1, 2006, titled Configurable Physiological Measurement System; U.S. Pat. Pub. No. 2006/0211925, filed Mar. 1, 2006, titled Physiological Parameter Confidence Measure and U.S. Pat. Pub. No. 2006/0238358, filed Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Monitor, all assigned to Cercacor Laboratories, Inc., Irvine, Calif. (Cercacor) and all incorporated in their entirety by reference herein. An advanced parameter measurement system that includes acoustic monitoring is described in U.S. Pat. Pub. No. 2010/0274099, filed Dec. 21, 2009, titled Acoustic Sensor Assembly, assigned to Masimo and incorporated in its entirety by reference herein.

Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SpO<sub>2</sub>, such as total hemoglobin (SpHb™), oxygen content (SpOC™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical-7™, Rad87™ and Rad57™ monitors, all available from Masimo. Advanced parameter measurement systems may also include acoustic monitoring such as acoustic respiration rate (RRa™) using a Rainbow Acoustic Sensor™ and Rad87™ monitor, available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.

### SUMMARY OF THE INVENTION

An avatar-incentive healthcare therapy system has a physiological monitor for generating a physiological parameter indicative of physical health. An academic test for generating a test score is indicative of mental acuity. The avatar has outward characteristics and game play capabilities proportional to the physiological health and the mental acuity so as to incentivize improved physical health and academic performance.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-B are perspective views of a physiological monitor and corresponding monitor screens incorporating avatar-incentives for healthcare therapy;

FIGS. 2A-C are avatar illustrations incorporating healthcare therapy incentives;

FIG. 3 are perspective views of physiological monitors and interfaced devices for incentivizing healthcare therapy;

FIG. 4 is a block diagram of physiological monitor communications for incentivizing healthcare therapy; and

FIG. 5 is a block diagram of a cloud-based physiological monitoring system for avatar-incentive healthcare therapy.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIGS. 1A-B illustrate a physiological monitor **100** and corresponding monitor screens **101**, **102** incorporating avatar-incentives for encouraging physical and mental fitness. As shown in FIG. 1A, the physiological monitor **100** has a handheld processing device **110**, a touch screen display **120**, a noninvasive optical sensor **130**, a sensor cable **140** electrically and mechanically interconnecting the processing device **110** and the sensor **130**, a monitor-integrated test strip reader **170** that accepts test strips **175**, one or more input keys **150** and an integrated camera **160** among other features. An optical sensor is described in detail with respect to U.S. Pat. No. 13/646,659 titled Noninvasive Blood Analysis System, filed Oct. 5, 2012, assigned to Cercacor and incorporated in its entirety by reference herein. A blood glucose monitor is described in detail with respect to U.S. patent Ser. No. 13/308,461 titled Handheld Processing Device Including Medical Applications for Minimally and Noninvasive Glucose Measurements, filed Nov. 30, 2011, assigned to Cercacor and incorporated in its entirety by reference herein. A blood glucose monitor and sensor are described in U.S. Ser. No. 13/473,477 titled Personal Health Device, filed May 16, 2012, assigned to Cercacor and incorporated in its entirety by reference herein.

As shown in FIG. 1B, in an embodiment, the touch screen display **120** has a physiological monitor display mode **101** and an incentive game play mode **102**. In a physiological monitor display mode **101**, the monitor displays measured physiological parameters. In an incentive game play mode **102**, the monitor constructs a video player avatar **180** having physical and mental strengths **190** based upon incentivizing criteria described below. In an embodiment, the avatar is inserted into physiological monitor-based video games according to its strengths **190** or exported externally to video games running on standalone video game systems or from the cloud, as described with respect to FIGS. 3-5, below.

Also shown in FIG. 1B, in an incentive game play mode **102**, the touch screen display **120** presents one or more video games advantageously incorporating a player avatar **180** that becomes stronger and/or smarter in proportion to the physical and/or mental capabilities of the player as an incentive for patient recovery. In an avatar communications mode, the player avatar and its corresponding physical and mental capabilities are communicated to an external video game system, as described with respect to FIGS. 3-5, below.

In an embodiment, an avatar summary screen **122** is presented in the game play mode **102** illustrating the player's selected avatar **180** and indicators **190** of the avatar's accumulated physical strength and mental prowess. With respect to physical strength, the physiological monitor **100** is in wireless or wired communications with, for example, exercise equipment so as to incentivize patients recovering from, say, accidents or surgery to track physical exercise and healing progress. With respect to mental prowess, the physiological monitor **100** is in communications with mental skill test results, where the mental skills are either presented by

the physiological monitor **100** itself in a mental challenge mode or input to the monitor **100** from external indicators of mental achievements, such as student report cards and standardized test results, to name a few.

In other embodiments, the physiological monitor **100** measures, records and tracks a person's physiological measurements such as resting heart rate, cholesterol and blood pressure among other physiological parameters. The person's avatar becomes physically stronger according to a health index based upon these parameters. Likewise, if a person passes certain quizzes or has a report card with straight A's, that person's avatar gets stronger and smarter for games simulating physical competition, such as racing, sports and combat. Advantageously, the physiological monitor **100** helps patients recovering from a stroke, provides a sports training tool for athletes and functions as a student teaching device, as a few examples.

FIGS. 2A-C illustrate avatars incorporating healthcare therapy incentives. As shown in FIG. 2A, a physiological monitor **110** (FIG. 1A) allows a patient or other user to construct an avatar **201**. The avatar's clothing or other external characteristics may overtly display the avatar's physical or mental strength **190** (FIG. 1B) as earned by the patient via improved physiological wellness or mental fitness tests measured by the monitor **110** (FIG. 1A) or provided externally, as described below. In an embodiment, the avatar has clothing **210** that reflects earned physical/mental accomplishments/improvements. In an exemplar embodiment, the avatar's belt color **212** indicates earned physical strength and the avatar's tunic or dress color **214** indicates earned mental strength. For example, a black belt **212** and a bright colored tunic **214** indicates an avatar with high physical and mental strength as the result of high physical and mental test scores and other real-world physical and mental accomplishments. As shown in FIG. 2B, earned avatar physical and mental strength are rewarded through video gaming, such as avatar combat, races and other player contests. As shown in FIG. 2C, avatar rewards may also be displayed on emails, Internet posts and other electronic communications.

FIG. 3 illustrate physiological monitors and interfaced devices for incentivizing healthcare therapy. The video game may be incorporated within one physiological monitor **301** for single player games or incorporated within linked physiological monitors **301**, **302** for multiple-player games, as described with respect to FIG. 4, below. Alternatively, a monitor **301** may be interfaced with an external video game system **320** that resides locally or in the cloud, such as an online gaming center **540** (FIG. 5). Physiological data for constructing an avatar's physical strength may be derived by a physiological monitor **301**, such as described with respect to FIG. 1, above, game play on an external video player **320**, data from wearable activity devices such as fitness bracelets **310**, data directly downloaded from a memory device such as a USB key **340** or from physiological data, game play, test scores, report cards **510-540** (FIG. 5) accessed via the cloud **10** (FIG. 5), as described with respect to FIG. 5, below. Similarly, mental prowess may be assessed by mental ability tests provided by the physiological monitor **301**, such as described with respect to FIG. 1, above, or from mental prowess data gathered via the cloud or other external sources, such as school grades and standardized test scores, as described with respect to FIG. 5, above. Video game play on a monitor **301** may also be enhanced by interfaced game play devices, such as a joystick **330**.

FIG. 4 illustrates physiological monitor communications for incentivizing healthcare therapy. A cloud-based monitor

5

communications system **400** has a cloud server **10** in communications with various physiological monitors **100**. In this manner, monitor users **20** may freely network with each other whether located in various hospitals/clinics **410**, at home **420**, on the street **430** or any location remote from the cloud server **10**. Data is transmitted from monitors **100** to the cloud server **10** via wired (e.g. LAN) or wireless (e.g. Wi-Fi) local networks to wide area media, such as Internet cable, telecommunications (e.g. 3G) networks or cellular networks **440**. These wide area media, in turn, are in communications with the cloud server **10**, which calculates physiological parameters or simply provides patient-to-patient communications including conversations or interactive gaming through their avatars, as described above.

FIG. 5 illustrates a cloud-based physiological monitoring system for avatar-incentive healthcare therapy. A healthcare monitor **560**, such as described with respect to FIG. 1 (**100**), above, incorporating earned avatar incentives, also described above, may be in communications with a physiological data processing center **510**, testing centers **520**, schools **530** and online gaming centers **540**. Physiological data for determining avatar physical strength may be determined from the physiological data processing center **510** and received by the monitor **560**. Likewise, data for determining avatar mental acuity may be determined from standardized testing centers **520**, e.g. from standard tests such as PSAT, SAT, GMAT, GRE etc. Avatar mental acuity may also be determined from various schools via authorized access to a particular student's grades **530**. Further, earned avatar incentives can be exported to and used within games provided by online gaming centers **540**. Avatar-incentive healthcare therapy has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications.

What is claimed is:

1. An electronic system for providing healthcare therapy, the electronic system comprising:

a first computing device comprising a hardware processor,  
a touch screen display, a first port configured to connect

6

with an optical sensor, and a second port configured to receive a measurement strip;

wherein the hardware processor is configured to determine a physiological parameter indicative of physical health of a person based on measurements acquired from the optical sensor and the measurement strip;

wherein the hardware processor is further configured to acquire an academic test score indicative of mental acuity of the person;

wherein the hardware processor is further configured to generate an avatar having outward characteristics and video game play capabilities proportional to the person's physical health and academic performance so as to incentivize exercise and study; and

wherein the avatar is simulated on the touch screen display.

2. The electronic system according to claim 1 wherein the avatar outward characteristics comprise an article of clothing having a color indicative of at least one of the person's physical health and academic performance.

3. The electronic system—according to claim 2 wherein the avatar game play capabilities comprise an apparent increase in avatar physical performance in proportion to an actual increase in the person's physical health.

4. The electronic system—according to claim 3 wherein the avatar game play capabilities comprise an apparent increase in avatar mental performance in proportion to an actual increase in the person's academic performance.

5. The electronic system—according to claim 4 further comprising communications between a physiological monitor and at least one external device so as to import information regarding the person's physical health and mental acuity and export information regarding the avatar.

6. The electronic system—according to claim 5 wherein the physiological parameter comprises at least one of heart rate and blood pressure.

7. The electronic system—according to claim 6 wherein the academic test score is determined using at least one standardized test.

\* \* \* \* \*

专利名称(译)	阿凡达 - 激励医疗保健疗法		
公开(公告)号	<a href="#">US10279247</a>	公开(公告)日	2019-05-07
申请号	US14/571286	申请日	2014-12-15
[标]申请(专利权)人(译)	梅西莫股份有限公司		
申请(专利权)人(译)	Masimo公司		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	KIANI MASSI JOE E		
发明人	KIANI, MASSI JOE E.		
IPC分类号	A63F13/212 A61B5/00 A61B5/0205 A61B5/024 A61B5/1455 A61B5/145 A61B5/021		
CPC分类号	A63F13/212 A61B5/0205 A61B5/744 A61B5/14532 A61B5/021 A61B5/024 A61B5/1455 A61B5/0022		
优先权	61/916136 2013-12-13 US		
其他公开文献	US20150165312A1		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

化身激励医疗保健治疗系统具有生理监测器，用于生成指示身体健康的生理参数。产生测试分数的学术测试表示精神敏锐度。化身具有与身体健康和心理敏锐度成比例的外在特征和游戏能力，以激励改善的身体健康和学习成绩。

